Search Results - Dun-Chang Mo

  • Showing 1 - 3 results of 3
Refine Results
  1. 1

    A pharmacovigilance analysis of post-marketing safety of durvalumab by An-Ju Tan, Wan-Ying Liu, Jun-Li Lu, Qing-Ying Tan, Yu Yan, Dun-Chang Mo

    Published in Scientific Reports (2025-05-01)
    Get full text
    Article


  2. 2

    The role of PD-L1 in patients with non-small cell lung cancer receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy: a meta-analysis by Dun-Chang Mo, Jian-Feng Huang, Peng Lin, Shang-Xiao Huang, Han-Lei Wang, Peng-Hui Luo, Xiu-Juan Liang

    Published in Scientific Reports (2024-10-01)
    Get full text
    Article


  3. 3

    Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis by Yao-Ning Feng, Guang-Yu Xie, Li Xiao, Dun-Chang Mo, Jian-Feng Huang, Peng-Hui Luo, Xiu-Juan Liang

    Published in Frontiers in Immunology (2023-06-01)
    Get full text
    Article


Search Tools: